Literature DB >> 22689337

Medication for psychosis--consumption and consequences: the second Australian national survey of psychosis.

Anna Waterreus1, Vera A Morgan, David Castle, Cherrie Galletly, Assen Jablensky, Patsy Di Prinzio, Sonal Shah.   

Abstract

BACKGROUND: Most people diagnosed with a psychotic disorder will be prescribed psychotropic medication. The second Australian national survey of psychosis provided a unique opportunity to examine the pharmacological treatment of psychotic disorders from the perspective of the consumer. The aim of this paper is to report on medication use, adherence and perceived efficacy, and to describe side effect profiles.
METHOD: Data on self-reported medication use in the 4 weeks prior to interview, including type, duration, adherence, side effects and helpfulness was collected from participants interviewed in the course of the second Australian national survey of psychosis.
RESULTS: The majority (91.6%) of participants were using psychotropic medication: 89.0% of people aged 18-34 years and 93.5% of people aged 35-64 years. The most commonly used class of medication was antipsychotic medication (81.6%). In addition, 37.4% were using antidepressants, 26.7% were using mood stabilisers and 17.8% were using anxiolytics/hypnotics. Polypharmacy was common with almost two-thirds (63.4%) using more than one class of medication and over a quarter (28.1%) of people with schizophrenia using more than one antipsychotic. Many participants (84.4%) reported experiencing side effects. The side effect profile of people using atypical antipsychotics was on average better than that of people using typical antipsychotics. Most people (85.2%) felt their medication relieved their mental health symptoms and most (88.2%) medication was taken as prescribed.
CONCLUSIONS: Many people with a psychotic disorder are receiving antipsychotics, with a substantial proportion also taking antidepressants, mood stabilisers and anxiolytics/hypnotics. Medication use differs by age group, diagnostic group and course of illness. Many people using antipsychotics describe significant impairment in their everyday life as a result of medication side effects. Users of typical antipsychotics reported more side effects and more impairment than people using atypical antipsychotics. Most of our participants were prescribed psychotropic medications, and most reported that they were taking them.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22689337     DOI: 10.1177/0004867412450471

Source DB:  PubMed          Journal:  Aust N Z J Psychiatry        ISSN: 0004-8674            Impact factor:   5.744


  13 in total

1.  Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies.

Authors:  John M Kane; Taishiro Kishimoto; Christoph U Correll
Journal:  World Psychiatry       Date:  2013-10       Impact factor: 49.548

2.  Comparison of longer-term safety and effectiveness of 4 atypical antipsychotics in patients over age 40: a trial using equipoise-stratified randomization.

Authors:  Hua Jin; Pei-an Betty Shih; Shahrokh Golshan; Sunder Mudaliar; Robert Henry; Danielle K Glorioso; Stephan Arndt; Helena C Kraemer; Dilip V Jeste
Journal:  J Clin Psychiatry       Date:  2012-11-27       Impact factor: 4.384

3.  Clozapine users in Australia: their characteristics and experiences of care based on data from the 2010 National Survey of High Impact Psychosis.

Authors:  D J Siskind; M Harris; A Phillipou; V A Morgan; A Waterreus; C Galletly; V J Carr; C Harvey; D Castle
Journal:  Epidemiol Psychiatr Sci       Date:  2016-07-18       Impact factor: 6.892

Review 4.  Medication nonadherence and psychiatry.

Authors:  Sarah C E Chapman; Rob Horne
Journal:  Curr Opin Psychiatry       Date:  2013-09       Impact factor: 4.741

5.  Socioeconomic status and prescribing for schizophrenia: analysis of 3200 cases from the Glasgow Psychosis Clinical Information System (PsyCIS).

Authors:  Daniel J Martin; John Park; Julie Langan; Moira Connolly; Daniel J Smith; Mark Taylor
Journal:  Psychiatr Bull (2014)       Date:  2014-04

6.  The Psychosis Recent Onset GRoningen Survey (PROGR-S): defining dimensions and improving outcomes in early psychosis.

Authors:  Edith J Liemburg; Stynke Castelein; Frank van Es; Anne Neeltje Scholte-Stalenhoef; Gerard van de Willige; Henderikus Smid; Ellen Visser; Henderikus Knegtering; Richard Bruggeman
Journal:  PLoS One       Date:  2014-11-20       Impact factor: 3.240

7.  Risk Factors for Obstructive Sleep Apnea Are Prevalent in People with Psychosis and Correlate with Impaired Social Functioning and Poor Physical Health.

Authors:  Dennis Liu; Hannah Myles; Debra L Foley; Gerald F Watts; Vera A Morgan; David Castle; Anna Waterreus; Andrew Mackinnon; Cherrie Ann Galletly
Journal:  Front Psychiatry       Date:  2016-08-31       Impact factor: 4.157

8.  Trends in the use of antipsychotics in the Israeli inpatient population, 2004-2013.

Authors:  Alexander M Ponizovsky; Eli Marom; Michal Ben-Laish; Igor Barash; Abraham Weizman; Eyal Schwartzberg
Journal:  Isr J Health Policy Res       Date:  2016-06-15

9.  Antipsychotic prescribing for vulnerable populations: a clinical audit at an acute Australian mental health unit at two-time points.

Authors:  Sara S McMillan; Sara Jacobs; Louise Wilson; Theo Theodoros; Gail Robinson; Claire Anderson; Gabor Mihala; Amanda J Wheeler
Journal:  BMC Psychiatry       Date:  2017-04-13       Impact factor: 3.630

10.  Efficacy and clinical determinants of antipsychotic polypharmacy in psychotic patients experiencing an acute relapse and admitted to hospital stay: results from a cross-sectional and a subsequent longitudinal pilot study.

Authors:  Felice Iasevoli; Elisabetta F Buonaguro; Massimo Marconi; Emanuela Di Giovambattista; Maria Paola Rapagnani; Domenico De Berardis; Giovanni Martinotti; Monica Mazza; Raffaele Balletta; Nicola Serroni; Massimo Di Giannantonio; Andrea de Bartolomeis; Alessandro Valchera
Journal:  ISRN Pharmacol       Date:  2014-01-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.